Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD.